lupron.com Report : Visit Site

Technical data of the lupron.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host lupron.com. Currently, hosted in United Kingdom and its service provider is Rackspace Ltd. .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

--- available by prescription only use and important safety information | prescribing information health care professionals please see important safety information you should know about lupron depot. health care professionals please see important safety information you should know about lupron depot. health care professionals please see important safety information you should know about lupron depot. health care professionals please see important safety information you should know about lupron depot-ped. health care professionals men prostate cancer women endometriosis women fibroids children central precocious puberty (cpp) men prostate cancer lupron depot ® (leuprolide acetate for depot suspension) 7.5 mg for 1-month, 22.5 mg for 3-month, 30 mg for 4-month, and 45 mg for 6-month administration are prescribed for the palliative treatment of advanced prostate cancer. lupron depot is a prescription medication that must be administered in your doctor’s office. please see the full prescribing information for lupron depot and discuss it with your doctor. safety considerations • lupron depot causes an increase in testosterone during the first few weeks of treatment • an increase in urinary symptoms and/or pain may occur • in patients whose cancer has spread to the spine or urinary tract, urinary blockage or pressure in the spine may occur and can lead to paralysis, which may be life-threatening • high blood sugar and an increased risk for developing diabetes, heart attack, sudden death, and stroke can occur with lupron depot treatment • lupron depot can affect the heart’s electrical activity in patients with certain heart conditions or abnormal blood tests for electrolytes, or who are taking medications that regulate the heartbeat • reports of convulsions have occurred in patients taking lupron depot with or without a history of seizures, epilepsy, or brain disorders (related to blood vessels, nerves, or tumors), or in those taking medicines that cause convulsions • lupron depot may cause impotence please see additional important safety information you should know about lupron depot and discuss it with your doctor. women endometriosis lupron depot ® (leuprolide acetate for depot suspension) 3.75 mg for 1-month and 11.25 mg for 3-month administration are used for the management of endometriosis, including pain relief and reduction of endometriotic lesions. lupron depot with daily norethindrone acetate 5 mg is also indicated for initial management of endometriosis and for management of recurrence of symptoms. the recommended initial treatment is no more than 6 months. repeat treatment for endometriosis should be limited to 6 months. please see the full prescribing information for lupron depot and discuss it with your doctor. safety considerations • you should not receive lupron depot if you are or may become pregnant, are breast-feeding or have undiagnosed vaginal bleeding • increased endometriosis symptoms (i.e. pelvic pain or pressure and/or pain during intercourse) may occur for 1 or 2 weeks after starting this drug • development or worsening of depression has occurred • a condom, a diaphragm with contraceptive jelly, or a copper iud is required to prevent pregnancy • thinning of the bones, which may not be completely reversible, can occur during treatment with this drug • reports of convulsions have occurred in patients taking leuprolide acetate • norethindrone acetate used as add-back therapy with lupron depot has additional serious risks and considerations • see the important safety information section for add-back risks and considerations please see additional important safety information you should know about lupron depot and discuss it with your doctor. women fibroids lupron depot ® (leuprolide acetate for depot suspension) 3.75 mg for 1-month and 11.25 mg for 3-month administration with iron therapy are used before fibroid surgery to improve anemia due to vaginal bleeding from fibroids. your doctor may consider a one-month trial of iron alone as some patients’ anemia will improve with iron alone. it is recommended that lupron depot not be used for more than 3 months in patients with fibroids. experience with lupron depot in females has been limited to women 18 years of age and older. please see the full prescribing information for lupron depot and discuss it with your doctor. safety considerations • you should not receive lupron depot if you are or may become pregnant, are breast-feeding or have undiagnosed vaginal bleeding • increased fibroid symptoms (i.e. abdominal bloating, pelvic pain or pressure) may occur for 1 or 2 weeks after starting this drug • development or worsening of depression has occurred • a condom, a diaphragm with contraceptive jelly, or a copper iud is required to prevent pregnancy • thinning of the bones, which may not be completely reversible, can occur during treatment with this drug • reports of convulsions have occurred in patients taking leuprolide acetate please see additional important safety information you should know about lupron depot and discuss it with your doctor. children central precocious puberty (cpp) lupron depot‑ped ® (leuprolide acetate for depot suspension) 7.5 mg, 11.25 mg, and 15 mg for 1-month and 11.25 mg and 30 mg for 3-month administration are prescribed for the treatment of children with central precocious puberty (cpp). doctors may diagnose children with cpp when signs of sexual maturity begin to develop in girls under the age of 8 or boys under the age of 9. your doctor should perform tests to rule out possible causes of early puberty that would require different treatment (e.g., tumors). it is not known if lupron depot-ped is safe and effective in children under 2 years of age. please see the full prescribing information for lupron depot-ped and discuss it with your doctor. safety considerations • your child should not receive lupron depot-ped if she/he is allergic to any of the ingredients or she is or may become pregnant. • increased signs and symptoms of puberty during the first few weeks of treatment may occur. • contact your child’s healthcare provider if signs of puberty continue after the second month of treatment or if new or unusual signs or symptoms occur. • mental (psychiatric) problems have been reported in patients taking gnrh agonists, like lupron depot-ped. events include emotional symptoms such as crying, irritability, restlessness (impatience), anger, and acting aggressive. • inform your child’s doctor right away if your child has any new or worsening mood symptoms while taking lupron depot-ped. • seizures have been observed in patients taking gnrh agonists, like lupron depot-ped, with or without a history of seizures, epilepsy, brain or brain vessel problems or tumors, and in patients taking medications that have been connected to seizures. • call your child’s doctor right away if your child has a seizure while taking lupron depot-ped. • your child’s pubertal development could begin again if the injection schedule is not followed. please see additional important safety information you should know about lupron depot-ped and discuss it with your doctor. click here to return to home if you or a loved one has been prescribed lupron depot, click on the specific condition to find out more about lupron depot therapy use and important safety information you should know about lupron depot ® (leuprolide acetate for depot suspension) use lupron depot ® (leuprolide acetate for depot suspension) 7.5 mg for 1-month, 22.5 mg for 3-month, 30 mg for 4-month, and 45 mg for 6-month administration are prescribed for the palliative treatment of advanced prostate cancer. lupron depot is a prescription medication that must be administered in your doctor’s office. important safety information lupron depot is not for people who have had any type of allergic reaction to lupron depot or similar drugs. lupron depot is not for women who are or may become pregnant. lupron depot causes an increase in tes

URL analysis for lupron.com

http://www.lupron.com/prescribing-information.aspx?ref=3
http://www.lupron.com/prescribing-information.aspx?ref=2
http://www.lupron.com/prescribing-information.aspx?ref=1
http://www.lupron.com/prescribing-information.aspx?ref=0
http://www.lupron.com/important-safety-information.aspx?ref=3
http://www.lupron.com/important-safety-information.aspx?ref=2
http://www.lupron.com/important-safety-information.aspx?ref=1
http://www.lupron.com/important-safety-information.aspx?ref=0
http://www.lupron.com/prescribing-information.aspx
http://www.lupron.com/important-safety-information.aspx
http://www.lupron.com/site-map.aspx
http://www.lupron.com/index.aspx

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: LUPRON.COM
Registry Domain ID: 2179855_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2017-05-31T09:15:26Z
Creation Date: 1997-07-03T04:00:00Z
Registry Expiry Date: 2018-07-02T04:00:00Z
Registrar: MarkMonitor Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.2083895740
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: ABVEGDMZNS1.ABBVIE.COM
Name Server: ABVLUDMZNS1.ABBVIE.COM
Name Server: ABVSGDMZNS1.ABBVIE.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-05-25T14:09:31Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR MarkMonitor Inc.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =lupron.com

  PORT 43

  TYPE domain

DOMAIN

  NAME lupron.com

  CHANGED 2017-05-31

  CREATED 1997-07-03

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  ABVEGDMZNS1.ABBVIE.COM 159.180.132.57

  ABVLUDMZNS1.ABBVIE.COM 159.180.162.57

  ABVSGDMZNS1.ABBVIE.COM 159.180.178.57

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .